Cytoplasmic and nuclear programmed death ligand 1 expression in peritumoral stromal cells in breast cancer: Prognostic and predictive value

Table 8 Results of univariate and multivariate analyses

Breast cancer characteristics	Univariate analysis OR (95%CI)	P value	Multivariate analysis OR (95%CI)	P value
T stage
Tis-T1b	1	> 0.05
T1c	1.08 (0.43-5.81)
T2	0.54 (0.11-3.96)
Tumor grade (G)
G1	1	0.05
G2	1.78 (0.59-5.31)
G3	0.86 (0.26-2.87)
Lymphovascular invasion
No	1	< 0.00001	1	< 0.00001
Yes	60.26 (21.60-168.1)		82.73 (24.02-284.89)
Perineural invasion
No	1	0.047	1	> 0.05
Yes	2.23 (1.01-4.91)		0.28 (0.07-1.19)
ER status
Negative	1	0.03	1	> 0.05
Positive	4.08 (1.11-14.98)		7.35 (0.91-59.45)
PR status
Negative	1	> 0.05
Positive	1.08 (0.25-2.23)
HER2 status
HER2 -	1	> 0.05
HER2+	0.47 (0.17-1.30)
Molecular biological subtype
Luminal A	1	> 0.05
Luminal B HER2-	1.08 (0.53-2.21)
Luminal B HER2+	1.73 (0.44-6.81)
Нелюминальный HER2+	0.57 (0.16-1.21)
TNBC	1.15 (0.21-6.22)
Vessels with PDCD1 LG1 expression
absent	1	0.08
present	1.81 (0.91-3.59)
PDCD1 LG1+ LF score
< 3	1	0.018	1	> 0.05
≥ 3	0.41 (0.20-0.86)		0.46 (0.14-1.48)
Combination of LVI and PDCD1 LG1+ LF score
LVI- and PDCD1 LG1+ LF score < 3	1	0.004	1
LVI- and PDCD1 LG1+ LF score ≥ 3	0.13 (0.03-0.53)		0.11 (0.02-0.46)	0.003
LVI+ and PDCD1 LG1+ LF score < 3	9.50 (2.21-40.79)	0.002	11.09 (2.31-53.15)	0.003
LVI+ and PDCD1 LG1+ LF score ≥ 3	25.33 (5.48-117.1)	< 0.00001	44.35 (7.35-267.5)	< 0.00001

CI: Confidence interval; ER: Estrogen receptor; HER2: Human epidermal growth factor receptor 2; LFs: Lymphocytes; LVI: Lymphovascular invasion; OR: Odds ratio; PDCD1 LG1: Programmed cell death protein 1 ligand 1; PR: Progesterone receptor; TNBC: Triple-negative breast cancer.